Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference

Rhea-AI Summary

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that CEO Alan H. Auerbach will present at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on demand starting January 11, 2021, at 6:00 a.m. EST, and accessible for 30 days on the company’s website.

Puma focuses on developing innovative cancer treatments, notably NERLYNX® (neratinib), approved for HER2-positive breast cancer. The FDA approved NERLYNX in 2017 for early-stage patients and in 2020 for advanced cases. For more information, visit www.pumabiotechnology.com.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on demand beginning at 6:00 a.m. EST on January 11, 2021.

The virtual presentation will be available for 30 days on the Company’s website at www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005550/en/

FAQ

What is Puma Biotechnology presenting at the H.C. Wainwright BioConnect Conference?

Puma Biotechnology will provide an overview of the company and its developments during the conference.

When will Puma Biotechnology's presentation be available?

The presentation will be available on demand starting at 6:00 a.m. EST on January 11, 2021.

How long will Puma Biotechnology's presentation be accessible?

The presentation will be available for 30 days on Puma's website.

What is NERLYNX® and its significance for Puma Biotechnology?

NERLYNX® (neratinib) is an FDA-approved treatment for HER2-positive breast cancer, enhancing Puma's portfolio in cancer care.

What are the recent FDA approvals for NERLYNX®?

NERLYNX was approved in 2017 for early-stage HER2-positive breast cancer and in 2020 for advanced cases.